<Anchor> The
European Medicines Agency has announced that the Janssen vaccine in the United States may cause side effects of blood clots. However, he did not recommend stopping the vaccination because the benefits of getting the vaccine were much greater.
Reporter Han Se-hyun reports.
<Reporter>
According to the results of its own investigation, the European Medicines Agency determined that the Janssen vaccine may have been associated with the previously reported side effects of blood clots in the United States.
[Dr. Sabine/Chairman of the European Medicines Agency's Safety Committee: We concluded that the Janssen vaccine may have been associated with the formation of blood clots due to platelet reduction.]
He then recommended that a warning about possible blood clots should be added to the product information.
In the United States, as of the 13th, more than 7 million people had received the Janssen vaccine, of which 8 side effects of blood clots were reported.
Side effects occurred within 3 weeks of vaccination, younger than 60 years of age, and were frequent in women.
On the basis of this, the US health authorities recommended the suspension of the Janssen vaccination on the 13th, followed by a decision to suspend and postpone the Janssen vaccination in various parts of the world.
However, the European Medicines Agency has not issued a separate recommendation for stopping vaccination or limiting the age.
They judged that the chances of side effects were very slim and that the benefits of vaccination outweighed stopping vaccination.
[Emer Cook/Director of the European Medicines Agency: The benefits of vaccination outweigh the risk of side effects.]
In the meantime, he advised to seek immediate medical attention if there were any signs of side effects.
Korea's health authorities signed a contract with Janssen to pre-purchase a vaccine for 6 million people, and they plan to decide on an inoculation plan after observing further safety discussions between the United States and the European Union.